Table 1
From: Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
Patients | 0m | 3m | 6m | Clinical course |
|---|---|---|---|---|
1 | - | - | - | Molecular relapse |
2 | - | - | - | CMR |
3 | - | - | + | CMR |
4 | - | - | - | CMR |
5 | - | - | - | CMR |
6 | - | + | - | CMR |
7 | - | - | - | CMR |
8 | - | - | - | Molecular relapse |
9 | - | - | - | CMR |
10 | - | - | - | CMR |
11 | - | - | - | Molecular relapse |
12 | - | - | - | Molecular relapse |
13 | - | - | - | CMR |
14 | + | - | - | CMR |
15 | - | - | - | CMR |
16 | - | - | - | CMR |